Positives

• Long COVID patients trying triple anticoagulation in South African clinics commonly report their shortness of breath, brain fog, concentration problems, and fatigue improving over a 3-4 week course, with microclot scores typically dropping from around 7 down to 5 Health Rising.
• A Drugs.com reviewer treated for a deep vein clot wrote rivaroxaban “did great for resolving a clot in a deep vein in my right leg,” though many other Xarelto reviewers describe overwhelming fatigue while on it Drugs.com.

Negatives

• One patient critiqued the same trial as "underpowered" and lacking a control group, arguing that the need for ongoing therapy to maintain improvement suggests microclots may be a downstream symptom rather than the root cause, and that this undercuts confidence in rivaroxaban-based protocols as a cure Phoenix Rising.
• A patient tracking the same research noted that a small minority of treated patients experienced severe bleeding complications or failed to respond at all, which is the central safety concern with the rivaroxaban-containing triple protocol Phoenix Rising.

Hurdles & Side Effects

• Because triple anticoagulation carries a real risk of dangerous bleeding, forum members consistently caution that the protocol requires close monitoring (INR or equivalent, hemoglobin trends, stool occult blood) and that patients on the protocol typically need to remain on some form of antithrombotic therapy indefinitely to avoid symptom relapse — which raises separate long-term bleeding concerns Phoenix Rising.